You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

 

Online download statistics by month:

Online download statistics by month: August 2024 to July 2025

AbstractFullPdf
Aug 202411201128442
Sep 2024315315210
Oct 2024318319189
Nov 2024273277134
Dec 2024271280115
Jan 2025273274195
Feb 2025203203137
Mar 2025197197105
Apr 2025218223129
May 2025212212133
Jun 2025206208112
Jul 2025110
Total360736371901